Clozapine produces potent antidopaminergic effects anatomically specific to the mesolimbic system

E. L. Gardner, J. Chen, William Paredes

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Although weak as an antagonist at brain dopamine receptors, clozapine is very strongly antidopaminergic when measured by in vivo single-neuron electrophysiologic recording, in vivo brain microdialysis, in vivo brain voltammetric electrochemistry, in vivo electrical brain stimulation, or in vivo neurobehavioral techniques. Three aspects of clozapine's strong antidopaminergic actions are remarkable. First, clozapine's antidopaminergic potency is stronger than can be explained by its comparatively weak interaction with dopamine receptors, implying that a significant portion of its antidopaminergic action may be transsynaptic and secondary to actions on nondopamine neurotransmitter systems. Second, clozapine's strong antidopaminergic action is seen more reliably with chronic rather than acute administration, implying that some cumulative neurochemical process underlies the gradual recruitment of dopamine blockade. Third, and most remarkably, clozapine's strong antidopaminergic action is anatomically specific-present in the mesolimbic dopamine system but absent in the nigrostriatal dopamine system. This mesolimbic-specific dopamine blockade may underlie at least a portion of clozapine's atypical clinical profile.

Original languageEnglish (US)
Pages (from-to)15-22
Number of pages8
JournalJournal of Clinical Psychiatry
Volume55
Issue number9 SUPPL. B
StatePublished - 1994

Fingerprint

Clozapine
Dopamine
Dopamine Receptors
Brain
Electrochemistry
Deep Brain Stimulation
Microdialysis
Neurotransmitter Agents
Neurons

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Clozapine produces potent antidopaminergic effects anatomically specific to the mesolimbic system. / Gardner, E. L.; Chen, J.; Paredes, William.

In: Journal of Clinical Psychiatry, Vol. 55, No. 9 SUPPL. B, 1994, p. 15-22.

Research output: Contribution to journalArticle

@article{886074c1ff974886b739392ca16ada5b,
title = "Clozapine produces potent antidopaminergic effects anatomically specific to the mesolimbic system",
abstract = "Although weak as an antagonist at brain dopamine receptors, clozapine is very strongly antidopaminergic when measured by in vivo single-neuron electrophysiologic recording, in vivo brain microdialysis, in vivo brain voltammetric electrochemistry, in vivo electrical brain stimulation, or in vivo neurobehavioral techniques. Three aspects of clozapine's strong antidopaminergic actions are remarkable. First, clozapine's antidopaminergic potency is stronger than can be explained by its comparatively weak interaction with dopamine receptors, implying that a significant portion of its antidopaminergic action may be transsynaptic and secondary to actions on nondopamine neurotransmitter systems. Second, clozapine's strong antidopaminergic action is seen more reliably with chronic rather than acute administration, implying that some cumulative neurochemical process underlies the gradual recruitment of dopamine blockade. Third, and most remarkably, clozapine's strong antidopaminergic action is anatomically specific-present in the mesolimbic dopamine system but absent in the nigrostriatal dopamine system. This mesolimbic-specific dopamine blockade may underlie at least a portion of clozapine's atypical clinical profile.",
author = "Gardner, {E. L.} and J. Chen and William Paredes",
year = "1994",
language = "English (US)",
volume = "55",
pages = "15--22",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "9 SUPPL. B",

}

TY - JOUR

T1 - Clozapine produces potent antidopaminergic effects anatomically specific to the mesolimbic system

AU - Gardner, E. L.

AU - Chen, J.

AU - Paredes, William

PY - 1994

Y1 - 1994

N2 - Although weak as an antagonist at brain dopamine receptors, clozapine is very strongly antidopaminergic when measured by in vivo single-neuron electrophysiologic recording, in vivo brain microdialysis, in vivo brain voltammetric electrochemistry, in vivo electrical brain stimulation, or in vivo neurobehavioral techniques. Three aspects of clozapine's strong antidopaminergic actions are remarkable. First, clozapine's antidopaminergic potency is stronger than can be explained by its comparatively weak interaction with dopamine receptors, implying that a significant portion of its antidopaminergic action may be transsynaptic and secondary to actions on nondopamine neurotransmitter systems. Second, clozapine's strong antidopaminergic action is seen more reliably with chronic rather than acute administration, implying that some cumulative neurochemical process underlies the gradual recruitment of dopamine blockade. Third, and most remarkably, clozapine's strong antidopaminergic action is anatomically specific-present in the mesolimbic dopamine system but absent in the nigrostriatal dopamine system. This mesolimbic-specific dopamine blockade may underlie at least a portion of clozapine's atypical clinical profile.

AB - Although weak as an antagonist at brain dopamine receptors, clozapine is very strongly antidopaminergic when measured by in vivo single-neuron electrophysiologic recording, in vivo brain microdialysis, in vivo brain voltammetric electrochemistry, in vivo electrical brain stimulation, or in vivo neurobehavioral techniques. Three aspects of clozapine's strong antidopaminergic actions are remarkable. First, clozapine's antidopaminergic potency is stronger than can be explained by its comparatively weak interaction with dopamine receptors, implying that a significant portion of its antidopaminergic action may be transsynaptic and secondary to actions on nondopamine neurotransmitter systems. Second, clozapine's strong antidopaminergic action is seen more reliably with chronic rather than acute administration, implying that some cumulative neurochemical process underlies the gradual recruitment of dopamine blockade. Third, and most remarkably, clozapine's strong antidopaminergic action is anatomically specific-present in the mesolimbic dopamine system but absent in the nigrostriatal dopamine system. This mesolimbic-specific dopamine blockade may underlie at least a portion of clozapine's atypical clinical profile.

UR - http://www.scopus.com/inward/record.url?scp=0027942053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027942053&partnerID=8YFLogxK

M3 - Article

C2 - 7961561

AN - SCOPUS:0027942053

VL - 55

SP - 15

EP - 22

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 9 SUPPL. B

ER -